{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:48:49Z","timestamp":1790174929490,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.dsx.2018.06.018","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T14:56:39Z","timestamp":1530802599000},"page":"1025-1030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The rate of progression of type 2 diabetes mellitus to end stage renal disease \u2013 A single centred retrospective study from Malaysia"],"prefix":"10.1016","volume":"12","author":[{"given":"Yen Ping","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guat See","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Ying","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9203-5259","authenticated-orcid":false,"given":"Ganesh Pandian","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Hoon","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 31","key":"10.1016\/j.dsx.2018.06.018_bib0005","first-page":"S62","article-title":"Position statement on diagnosis and classification of diabetes mellitus","author":"The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2018.06.018_bib0010","series-title":"Kidney disease of diabetes","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2014"},{"key":"10.1016\/j.dsx.2018.06.018_bib0015","series-title":"United States renal data system. USRDS 2007 annual data report","author":"Bethesda","year":"2007"},{"key":"10.1016\/j.dsx.2018.06.018_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jcp.2005.035592","article-title":"Distinguishing diabetes nephropathy from other causes of glomerulosclerosis: an update","volume":"60","author":"Alsaad","year":"2007","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.dsx.2018.06.018_bib0025","first-page":"1","article-title":"Onset of end-stage renal disease and prevalence of vascular diseases at the start of dialysis in type 2 diabetic patients with diabetic and vascular nephropathy","volume":"3","author":"Biensenbach","year":"2014","journal-title":"Endocrinol Metab Syndr"},{"key":"10.1016\/j.dsx.2018.06.018_bib0030","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/BF02374504","article-title":"Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin dependent) diabetic nephropathy","volume":"36","author":"Pugh","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2018.06.018_bib0035","doi-asserted-by":"crossref","first-page":"c317","DOI":"10.1159\/000328909","article-title":"Diabetic nephropathy in the Arab Gulf countries","volume":"119","author":"Farag","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"10.1016\/j.dsx.2018.06.018_bib0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ndt\/16.2.286","article-title":"Variation in the progression of diabetic nephropathy according to racial origin","volume":"16","author":"Earle","year":"2001","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.dsx.2018.06.018_bib0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/nep.12379","article-title":"Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster","volume":"20","author":"Loh","year":"2015","journal-title":"Nephrology"},{"key":"10.1016\/j.dsx.2018.06.018_bib0050","volume":"volume III","author":"National Health and Morbidity Survey","year":"2015"},{"key":"10.1016\/j.dsx.2018.06.018_bib0055","series-title":"The national renal registry","author":"21st Report of The Malaysian Dialysis & Transplant Registry","year":"2013"},{"key":"10.1016\/j.dsx.2018.06.018_bib0060","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/BF02374503","article-title":"Determinants of end-stage renal disease in Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus and proteinuria","volume":"36","author":"Nelson","year":"1993","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.dsx.2018.06.018_bib0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2018.06.018_bib0070","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"For the diabetics exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"NEJM"},{"key":"10.1016\/j.dsx.2018.06.018_bib0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systemic review","volume":"329","author":"Gf","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2018.06.018_bib0080","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease","author":"Strippoli","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.dsx.2018.06.018_bib0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dsx.2018.06.018_bib0090","unstructured":"National Diabetes Registry Report (2009\u20132012) Voulme 1, Ministry of Health Malaysia."},{"key":"10.1016\/j.dsx.2018.06.018_bib0095","first-page":"76","article-title":"An audit of diabetes control and manaement (ADCM)","volume":"76","author":"Mastura","year":"2014","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.dsx.2018.06.018_bib0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.dsx.2018.06.018_bib0105","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes mellitus","volume":"345","author":"Parving","year":"2001","journal-title":"NEJM"},{"key":"10.1016\/j.dsx.2018.06.018_bib0110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000112270","article-title":"Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease","volume":"28","author":"Palmer","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.dsx.2018.06.018_bib0115","series-title":"Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia","author":"Ahmad","year":"2013"},{"issue":"148","key":"10.1016\/j.dsx.2018.06.018_bib0120","article-title":"Complementary and alternative medicine use among patients with type 2 diabetes mellitus in the primary care settings: a cross sectional study in Malaysia","volume":"13","author":"Ching","year":"2013","journal-title":"Biomed Central"},{"issue":"9","key":"10.1016\/j.dsx.2018.06.018_bib0125","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-131-9-199911020-00005","article-title":"The cost effectiveness of treating all type 2 diabetes with angiotensin converting enzyme inhibitors","volume":"131","author":"Golan","year":"1999","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.dsx.2018.06.018_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026139","article-title":"Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands \u2013 a markov model","volume":"6","author":"Adarkwah","year":"2011","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1016\/j.dsx.2020.12.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000}}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402118302443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402118302443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T12:38:32Z","timestamp":1536583112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402118302443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1871402118302443"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2018.06.018","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.dsx.2020.12.005","asserted-by":"object"}]},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rate of progression of type 2 diabetes mellitus to end stage renal disease \u2013 A single centred retrospective study from Malaysia","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2018.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}